PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 20261 citations

Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.

View Full Paper
NCNicholas J. CampionDPDioni-Pinelopi PetsiouFFFlorian C Fally

Key Points

  • Explore the long-term effects of dupilumab with extended dosing intervals in managing CRSwNP.
  • Evaluated the effects of personalized dosing intervals of dupilumab over five years.
  • Monitored disease control and safety profiles of patients during the treatment.
  • Analyzed changes in treatment burden and side effects associated with any dosing adjustments.
  • Dupilumab therapy provided sustained disease control over five years.
  • Extended dosing intervals maintained efficacy while reducing overall treatment burden.
  • Safety profiles remained excellent throughout the treatment period.

Abstract

Long-term dupilumab therapy provided durable disease control and excellent safety. Personalized dosing-interval extension maintained efficacy and reduced treatment burden, supporting its potential role in optimizing long-term management of CRSwNP, especially in patients with troublesome side effects.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Campion et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd3dd48f933b5eed96e3https://doi.org/10.1002/alr.70125
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term dupilumab therapy reduces concomitant medication use in patients with CRSwNP.2026
  2. 2Two‐Year Turning Point With Dupilumab in CRSwNP: Control, Remission, and Tapering Dosage2025
  3. 3Dupilumab Extended Interval Dosing in Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta‐analysis2026
  4. 4Extended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study2026
  5. 5A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension2026